Doxorubicin Toxicity Assay
Doxorubicin Toxicity Assay - Related Videos
09:56
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
0 Views •
Cited by 22 •
2016
A protocol for the preparation and characterization of lipophilic doxorubicin pro-drug loaded 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG) micelles is described.
09:06
Growth Assays to Assess Polyglutamine Toxicity in Yeast
0 Views •
Cited by 3 •
2012
This manuscript describes three complementary protocols for assessing the toxicity of polyglutamine (polyQ)-expansion proteins in the yeast Saccharomyces cerevisiae. These protocols can easily be modified to monitor the toxicity of other misfolded proteins in yeast.
02:56
C. elegans Survival Assay: A Short-Term Toxicity Test
0 Views •
2023
This video introduces a short-term survival assay that tests a treatment for acute toxicity or tests a genetic strain for resistance to a toxic condition. The example protocol shows an example survival assay in which worms are tested for their ability to resist oxidative stress induced by paraquat (PQ).
13:59
Assaying β-amyloid Toxicity using a Transgenic C. elegans Model
0 Views •
Cited by 76 •
2010
The intensely studied nematode worm Caenorhabditis elegans can be transgenically engineered to express the human β-amyloid peptide (Aβ). Induced expression of Aβ in C. elegans muscle leads to a rapid, reproducible paralysis phenotype that can be used to monitor treatments that modulate Aβ toxicity.
02:05
Evaluating Bacterial Virulence Using the C. elegans Liquid Toxicity Assay
0 Views •
2026
Source: Chen, Y., et al. Evaluating Virulence and Pathogenesis of Aeromonas Infection in a Caenorhabditis elegans Model. J. Vis. Exp. (2018).This video demonstrates the C. elegans Liquid Toxicity Assay with Aeromonas, a method used to evaluate bacterial virulence by measuring worm survival in a nutrient-limited liquid environment. The assay reveals strain-specific pathogenicity based on the extent of toxin-induced damage and mortality in C. elegans.
FAQs
Doxorubicin can disrupt cell function through several interacting mechanisms. It intercalates, or inserts, between DNA bases, interferes with topoisomerase II activity, and promotes oxidative stress. Assessing these effects together helps researchers connect a measured loss of viability or function with the underlying forms of drug-induced cellular damage.
The combined effects of DNA damage-related interference and oxidative stress mean that a single response measurement may not capture the full impact of exposure. Comparing metabolic activity, membrane integrity, and cell-death indicators provides complementary evidence, helping distinguish reduced cellular function from broader loss of membrane stability or survival.
Metabolic activity indicates whether exposed cells or engineered tissues retain functional cellular activity, while membrane integrity reflects damage to the cell boundary. Cell-death measurements add another level of assessment. Together, these readouts show whether doxorubicin primarily reduces function, compromises structural integrity, or produces a more extensive toxic response.
The assay establishes defined doxorubicin concentrations and applies them to cultured cells or engineered tissues under controlled laboratory conditions. Researchers then measure selected responses after exposure, such as metabolic activity, membrane integrity, or cell death. Keeping concentrations and test conditions defined supports meaningful comparisons among samples and experimental designs.
Bioengineers can use the assay to compare how biomaterials or drug-delivery systems influence cellular responses to doxorubicin. Testing these systems with cultured cells, engineered tissues, or organoids reveals differences in apparent drug sensitivity and damage. The results can guide selection and optimization of designs intended to deliver treatment more effectively or safely.
Dose-response data show how cellular or tissue responses change across defined doxorubicin concentrations. In bioengineering, these patterns support safety evaluation, comparison of engineered tissues and organoids, and refinement of therapeutic designs. They also help assess whether a targeted delivery strategy changes the observed toxicity profile relative to the tested exposure conditions.